抑制TGF-β通路可保护脓毒症大鼠膈肌免于萎缩和无力
研究在大鼠盲肠结扎穿孔所致慢性脓毒症(7天)模型中,观察TGF-β抑制剂LY364947对膈肌的影响。大鼠分为对照组、脓毒症组、脓毒症第0天起给药组(LY D0)和第1天起给药组(LY D1)。慢性脓毒症导致体重、摄食量和膈肌质量下降;仅LY D1组膈肌萎缩被消除,且仅LY D1组膈肌收缩功能获益。脓毒症组SMAD3过表达并磷酸化,LY364947可逆转该效应;脓毒症组钙蛋白酶-1、钙蛋白酶-2及MAFbx过表达,LY364947降低钙蛋白酶-1和MAFbx表达。作者首次证明慢性脓毒症期间抑制TGF-β通路可在感染后第1天即保护膈肌免于萎缩和无力。
要点
- 大鼠盲肠结扎穿孔慢性脓毒症7天模型中,脓毒症导致体重、摄食量和膈肌质量下降。
- 仅从感染第1天起给予LY364947的LY D1组膈肌萎缩被消除,第0天起给药的LY D0组未见此效应。
- 仅LY D1组膈肌收缩功能从LY364947获益。
- 脓毒症组SMAD3过表达并磷酸化,LY364947可逆转;脓毒症组钙蛋白酶-1、钙蛋白酶-2及MAFbx过表达,LY364947降低钙蛋白酶-1和MAFbx表达。
- 作者认为慢性脓毒症期间抑制TGF-β通路可保护膈肌免于萎缩和无力,可能改善ICU脓毒症患者的治疗与护理。
适用人群与场景
- 大鼠盲肠结扎穿孔所致慢性脓毒症模型,实验持续7天。
处置流程与药物剂量
- TGF-β抑制剂LY364947:脓毒症大鼠分别从第0天(LY D0组)或第1天(LY D1组)起给药;原文未写明剂量、途径和频次。
研究设计与关键结果
- 研究类型:大鼠实验研究;样本量原文未报告;分组为对照组、脓毒症组、脓毒症第0天起LY364947组(LY D0)、脓毒症第1天起LY364947组(LY D1)。
- 慢性脓毒症导致体重、摄食量和膈肌质量下降;仅LY D1组膈肌萎缩被消除。
- LY364947仅对LY D1组膈肌收缩产生有益效应。
- 脓毒症组SMAD3过表达并磷酸化,LY364947可逆转该效应。
- 脓毒症组钙蛋白酶-1、钙蛋白酶-2及MAFbx过表达;LY364947降低钙蛋白酶-1和MAFbx表达。
证据类型、等级与局限
- 证据类型:动物实验(大鼠);原文未给出证据等级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,慢性脓毒症期间抑制TGF-β通路可保护膈肌免于萎缩和无力,可能为ICU脓毒症患者带来更有效的治疗和护理。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Sepsis is a frequent complication in patients in intensive care units (ICU). Diaphragm weakness, one of the most common symptoms observed, can lead to weaning problems during mechanical ventilation. Over the last couple of years, members of the transforming growth factor (TGF) β family, such as myostatin, activin A, and TGF-β1, have been reported to strongly trigger the activation of protein breakdown involved in muscle wasting. The aim of this study was to investigate the effect of TGF-β inhibitor LY364947 on the diaphragm during chronic sepsis.Rats were separated into four groups exposed to different experimental conditions: Control group, Septic group, Septic group with inhibitor from day 0 (LY D0), and Septic group with inhibitor from day 1 (LY D1). Sepsis was induced in rats by cecal ligation and puncture, and carried out for 7 days.Chronic sepsis was responsible for a decrease in body weight, food intake and diaphragm's mass. The inhibitor was able to abolish diaphragm wasting only in the LY D1 group. Similarly, LY364947 had a beneficial effect on the diaphragm contraction only for the LY D1 group. SMAD3 was over-expressed and phosphorylated within rats in the Septic group; however, this effect was reversed by LY364947. Calpain-1 and -2 as well as MAFbx were over-expressed within individuals in the Septic group. Yet, calpain-1 and MAFbx expressions were decreased by LY364947.With this work, we demonstrate for the first time that the inhibition of TGF-β pathway during chronic sepsis protects the diaphragm from wasting and weakness as early as one day post infection. This could lead to more efficient treatment and care for septic patients in ICU.
参考来源
- Jude B, Tissier F, Dubourg A, et al. TGF-β Pathway Inhibition Protects the Diaphragm From Sepsis-Induced Wasting and Weakness in Rat. Shock. 2020. PMID: 32413000. doi:10.1097/SHK.0000000000001393
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。